Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05950087

Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy

Cervical cancer CC is the most common malignant tumor in the female reproductive system, seriously endangering women's health and life, and is one of the leading causes of death for women worldwide.Globally, HPV causes about 85% of cervical cancers and about 60% of oropharyngeal cancers, causing more than 500,000 cancers each year.ctDNA is a potential biomarker because it contains tumor-specific genetic and epigenetic abnormalities that can be used in cancer diagnosis and prognosis prediction.MRD is considered a promising prognostic marker that can be used to identify individuals at increased risk of recurrence and individuals who may benefit from treatment.The expression level of MRD and plasma HPV before and after radiotherapy and chemotherapy for cervical cancer was analyzed by liquid biopsy ctDNA detection technology, which predicted the efficacy of cervical cancer radiotherapy and chemotherapy, which was helpful for monitoring and estimating the risk of disease recurrence after cervical cancer radiotherapy and chemotherapy, and verified the expression of MRD and plasma HPV as the basis for adjuvant chemotherapy after cervical cancer radiotherapy and the basis for optimal chemotherapy time node selection.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Locally Advanced Cervical Cancer

Age range

18 year–75 year

Sex eligibility

Female

Study type

Observational

Primary location

About this study

Current treatments for cervical cancer include surgery, radiotherapy, chemotherapy, and immunotherapy. However,5 year survival remains unsatisfactory because most patients with cervical cancer are typically diagnosed locally advanced or have distant lymph node metastases.HPV can integrate its own genome into the host genome by disrupting the open reading frame of the E2 gene and increase the expression of the E6 and E7 genes. The p53 protein of the host cell is degraded by the production of the E6 virulent protein, which inactivates the pRb protein that controls the cell cycle, thereby cancerizing the entire host cell [6]. According to TCGA 2017 data, HPV integration into the host genome was found in more than 80% of HPV-positive cervical cancer patients. Han K et al. found that HPV testing can assess the prognosis of cervical cancer patients.Circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating tumor RNA (ctRNA), exosomes, proteins, and metabolites that are liquid biopsy analytes can be identified using biomarkers such as somatic point mutations, deletions, amplification, gene fusion, DNA methylation markers, miRNAs, proteins, or metabolites.Minimal tumor residual (MRD) refers to the residual tumor cells or biomarkers in the body after local or systemic cancer treatment, the activation of which can promote tumor metastasis and recurrence, also known as minimal residual disease, measurable residual disease, and molecular residual disease.Recently, the use of ctDNA analysis to determine MRD in solid tumors after intention-to-treat treatment and before clinical or radiological disease recurrence has shown significant therapeutic promise. In addition, MRD identification by ctDNA analysis correlates with poor prognosis in patients with malignant tumors.This project will use liquid biopsy ctDNA detection technology to analyze the expression level of MRD and plasma HPV before and after radiotherapy and chemotherapy for cervical cancer, predict the efficacy of radiotherapy and chemotherapy for cervical cancer, help monitor and estimate the risk of disease recurrence after radiotherapy and chemotherapy for cervical cancer, verify the expression of MRD and plasma HPV as the basis for adjuvant chemotherapy after radiotherapy and chemotherapy for cervical cancer and the basis for the selection of the optimal chemotherapy time, so as to provide clinically useful tumor markers for cervical cancer patients and reduce the mortality rate of cervical cancer.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: ≥ 18 years old, ≤ 75 years old.
  • Pathological histologic confirmation of cervical cancer.
  • Imaging or PET/CT examination can be performed to understand the tumor and complete all follow-up.
  • Measurable lesions before treatment.
  • Good physical condition: ECOG score 0-1 (or KPS score 70-100).
  • Estimated survival≥ 6 months.
  • The baseline blood routine and biochemical indexes before radiotherapy and chemotherapy met the following standards: hemoglobin ≥ 80g/L, absolute neutrophil count (ANC) ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT, AST ≤ 2.5 times the normal upper limit; Serum albumin ≥ 30 g/L.
  • There are three preoperative items: if the patient has syphilis, plum repellent therapy is required before treatment.
  • The patient has no history of allergy to rubber products.
  • Cardiopulmonary function is basically normal

Exclusion criteria

  • Those who are allergic to rubber products.
  • Those with severe acute infection and uncontrolled or purulent and chronic infection wounds that do not heal, chronic hepatitis B active stage, active tuberculosis, syphilis outbreak and AIDS.
  • Patients with pre-existing severe heart disease, including: congestive heart failure, uncontrollable high-risk arrhythmia, unstable angina, myocardial infarction, severe valvular heart disease, and intractable hypertension.
  • Those with neurological or psychiatric diseases or mental disorders that are not easy to control, poor compliance, unable to cooperate with and describe treatment responses, uncontrolled primary brain tumors or central nervous system metastases, and those with obvious cranial hypertension signs or neuropsychiatric symptoms.
  • with malignant serous effusion.
  • History of severe enteritis and cystitis, bleeding, intestinal perforation, rectovaginal fistula, rectoval bladder fistula, etc.
  • Those who have participated in other clinical trials.
  • Other situations in which the investigator believes that the subject is not suitable to participate in this experiment

Treatment and study plan

concurrent chemoradiotherapy

Other

Concurrent chemoradiotherapy

Primary outcomes

  1. Expression levels of MRD

    Time frame: Before chemoradiotherapy

    Blood collected by patients prior to concurrent chemoradiotherapy were tested to observe the expression levels of MRD

  2. Positive expression of plasma HPV

    Time frame: Before chemoradiotherapy

    Tissue samplescollected by patients prior to concurrent chemoradiotherapy were tested to observe the positive expression of plasma HPV

  3. Expression levels of MRD

    Time frame: During concurrent chemoradiotherapy, up to 6 weeks

    Blood collected in concurrent chemoradiotherapy were examined to observe the expression levels of MRD

  4. Positive expression of plasma HPV

    Time frame: During concurrent chemoradiotherapy,up to 6 weeks

    Tissue samples collected in concurrent chemoradiotherapy were examined to observe the positive expression of plasma HPV

  5. Expression levels of MRD

    Time frame: 4 weeks after the end of concurrent chemoradiotherapy

    Blood collected 4 weeks after the end of concurrent chemoradiotherapy were tested to observe the expression levels of MRD

  6. Positive expression of plasma HPV

    Time frame: 4 weeks after the end of concurrent chemoradiotherapy

    Tissue samples collected 4 weeks after the end of concurrent chemoradiotherapy were tested to observe the positive expression of plasma HPV

  7. Expression levels of MRD

    Time frame: 12 weeks after the end of concurrent chemoradiotherapy

    Blood collected 12 weeks after the end of concurrent chemoradiotherapy were tested to observe the expression levels of MRD

  8. Positive expression of plasma HPV

    Time frame: 12 weeks after the end of concurrent chemoradiotherapy

    Blood and tissue samples collected 12 weeks after the end of concurrent chemoradiotherapy were tested to observe the positive expression of plasma HPV

  9. Expression levels of MRD

    Time frame: 24 weeks after the end of concurrent chemoradiotherapy

    Blood and tissue samples collected by patients 24 weeks after the end of concurrent chemoradiotherapy were tested to observe the expression levels of MRD

  10. Positive expression of plasma HPV

    Time frame: 24 weeks after the end of concurrent chemoradiotherapy

    Blood and tissue samples collected by patients 24 weeks after the end of concurrent chemoradiotherapy were tested to observe the positive expression of plasma HPV

Study contacts

Contact information is provided by the study sponsor or research team.

Yong Li, Chief physician

CONTACT

[email protected]

13628566285

Sponsors and collaborators

Lead sponsor

Guizhou Provincial People's Hospital

Other

Registry information

Important dates

Study start
2022
Primary completion
2024
Study completion
2026
First posted
Jul 18, 2023
Registry last updated
Jul 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.